Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade-Reference-Cited by-同舟云学术

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade

Published:2018-08-28 Issue:16 Volume:132 Page:1675-1688
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Minnie Simone A.¹²^ORCID,Kuns Rachel D.¹,Gartlan Kate H.¹²,Zhang Ping¹,Wilkinson Andrew N.¹,Samson Luke¹,Guillerey Camille¹²,Engwerda Christian¹,MacDonald Kelli P. A.¹,Smyth Mark J.¹,Markey Kate A.¹²³,Vuckovic Slavica²⁴^ORCID,Hill Geoffrey R.¹³⁵

Affiliation:

1. QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia;

2. School of Medicine, The University of Queensland, Herston, QLD, Australia;

3. Department of Haematology and Bone Marrow Transplantation, The Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia;

4. Multiple Myeloma Research Group, Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; and

5. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Abstract

Key Points Myeloma promotes CD8+ T-cell exhaustion and IL-10 secretion from dendritic cells. PD-1 and TIGIT-targeted checkpoint inhibition is effective after SCT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/16/1675/1503075/blood825240.pdf

Reference53 articles.

1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017

2. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study;Cavo;Lancet,2010

3. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies;Moreau;J Clin Oncol,2011

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;N Engl J Med,1996

5. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting TIGIT for cancer immunotherapy: recent advances and future directions;Biomarker Research;2024-01-16

2. Immunocompetent Mouse Models of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-01

3. Immune-Pathogenesis of Myeloma;Hematology/Oncology Clinics of North America;2024-01

4. Current use of bispecific antibodies to treat multiple myeloma;Hematology;2023-12-08

5. Phytochemicals in regulating PD‐1/PD‐L1 and immune checkpoint blockade therapy;Phytotherapy Research;2023-12-05